NYSE$USPH
US Physical Therapy Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Second quarter results reported with management raising earnings guidance and increasing quarterly dividend.
U.S. Physical Therapy reported record-high net revenues and average visits per clinic per day for the second quarter of 2021. Management raised earnings guidance and increased the quarterly dividend due to the Company's strong performance.
- Operating Results per diluted share was $0.96, a record-high for the Company.
- Adjusted EBITDA was $21.8 million, a record-high for the Company.
- Average visits per clinic per day was 30.0, the highest number in the Company’s history.
- Net revenues was $126.9 million, a record-high for the Company.
Headline financials
Revenue & EPS history
US Physical Therapy · Revenue · Quarterly
$127M
Revenue by segment
US Physical Therapy · $203M total across 2 segments · Q4 2025
- Physical Therapy Operations$174M+13.0%85.8%
- Injury Prevention$28.7M+8.7%14.2%
Forward guidance
Management expects the Company’s Operating Results for 2021 to be in the range of $39.4 million to $40.6 million, or $3.05 to $3.15 per diluted share.
Tailwinds
- Strong performance for the 2021 Second Quarter.
- Impact of the acquisition closed in the 2021 Second Quarter.
- Confidence in the sustainability of the Company’s performance through the remainder of 2021.
- Estimated annual effective tax rate of approximately 27.0%.
- Excludes expenses associated with the previously-announced retirement and replacement of one of the Company’s co-Chief Operating Officers.
Headwinds
- Earnings guidance represents projected Operating Results from existing operations and excludes future acquisitions.
- The annual guidance figures will not be updated unless there is a material development that causes management to believe that Operating Results will be significantly outside the given range.
- occurrence of the multiple effects of the impact of public health crises and epidemics/pandemics, such as the novel strain of COVID-19 (coronavirus) which the financial magnitude and timing cannot be estimated
- changes as the result of government enacted national healthcare reform
- changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status, including the Medicare reimbursement reductions
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
-0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.5%
Avg return
30 days after
53%
35 / 66 earnings
Positive
+17.3%
Q3 2024
Best reaction
-27.5%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.5% | +1.3% | — | |
| Q4 2025 | -2.9% | +1.9% | -8.5% | |
| Q3 2025 | +0.9% | -15.8% | -13.8% | |
| Q2 2025 | +14.7% | +20.4% | +17.8% | |
| Q1 2025 | -0.1% | +8.8% | +8.9% | |
| Q4 2024 | -6.0% | -9.5% | -18.0% | |
| Q3 2024 | +17.3% | +14.8% | +17.9% | |
| Q2 2024 | -6.8% | -3.9% | -5.4% | |
| Q1 2024 | -2.2% | +0.2% | -8.0% | |
| Q4 2023 | +3.4% | +2.8% | +9.8% | |
| Q3 2023 | -2.8% | -3.3% | +4.3% | |
| Q2 2023 | -8.6% | -8.1% | -19.8% | |
| Q1 2023 | +4.5% | +10.1% | +2.1% | |
| Q4 2022 | +2.1% | +2.2% | -5.7% | |
| Q3 2022 | -8.9% | -4.0% | -0.3% | |
| Q2 2022 | -27.5% | -29.9% | -37.0% | |
| Q1 2022 | -4.4% | -4.1% | +4.2% | |
| Q4 2021 | -5.8% | -6.5% | -2.1% | |
| Q3 2021 | -3.6% | -8.2% | -21.6% | |
| Q2 2021 | -3.6% | -5.4% | -1.1% | |
| Q1 2021 | +6.0% | +4.5% | +6.6% | |
| Q4 2020 | -17.2% | -19.8% | -24.3% | |
| Q3 2020 | +8.4% | +26.6% | +29.2% | |
| Q2 2020 | +2.4% | +1.1% | +3.7% | |
| Q1 2020 | -1.0% | +2.7% | +0.9% | |
| Q4 2019 | -17.7% | -16.0% | -49.0% | |
| Q3 2019 | -20.1% | -20.4% | -20.5% | |
| Q2 2019 | +3.9% | +6.1% | +8.1% | |
| Q1 2019 | +2.3% | +3.3% | -1.2% | |
| Q4 2018 | +3.2% | +3.4% | +2.1% | |
| Q3 2018 | +5.1% | +6.5% | +10.7% | |
| Q2 2018 | +8.9% | +7.0% | +18.9% | |
| Q1 2018 | -1.4% | -0.5% | +2.4% | |
| Q4 2017 | +6.8% | +2.7% | +4.9% | |
| Q3 2017 | -2.6% | -2.9% | +5.7% | |
| Q2 2017 | +2.4% | +2.6% | -2.9% | |
| Q1 2017 | -6.0% | +0.8% | -2.1% | |
| Q4 2016 | +1.7% | +2.0% | -1.2% | |
| Q3 2016 | -1.2% | +0.5% | +14.3% | |
| Q2 2016 | +4.7% | +4.0% | +9.7% | |
| Q1 2016 | +12.7% | — | — | |
| Q4 2015 | +1.2% | — | — | |
| Q3 2015 | +2.3% | — | — | |
| Q2 2015 | -5.0% | — | — | |
| Q1 2015 | +7.9% | — | — | |
| Q4 2014 | +5.4% | — | — | |
| Q3 2014 | -7.2% | — | — | |
| Q2 2014 | +5.8% | — | — | |
| Q1 2014 | +3.0% | — | — | |
| Q4 2013 | -0.3% | — | — | |
| Q3 2013 | -7.1% | — | — | |
| Q2 2013 | +6.0% | — | — | |
| Q1 2013 | +3.5% | — | — | |
| Q4 2012 | -4.6% | — | — | |
| Q3 2012 | +0.6% | — | — | |
| Q2 2012 | +0.6% | — | — | |
| Q1 2011 | +1.0% | — | — | |
| Q1 2012 | +2.1% | — | — | |
| Q4 2009 | -0.2% | — | — | |
| Q4 2011 | -0.2% | — | — | |
| Q3 2010 | +1.9% | — | — | |
| Q3 2011 | +1.9% | — | — | |
| Q2 2011 | -10.9% | — | — | |
| Q4 2010 | -10.9% | — | — | |
| Q2 2010 | -10.9% | — | — | |
| Q1 2010 | +12.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro